LEASE by and between WEXFORD-UCSC II, LP, a Delaware limited partnership and SPARK THERAPEUTICS, INC.,Lease • March 14th, 2016 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
New Markets Tax Credits: This building/Project was financed in part with a Federal subsidy called New Markets Tax Credits (NMTC). The NMTC Program was established by Congress in 2000 to spur new or increased investments into operating businesses and real estate projects located in low-income communities. Communities benefit from the jobs associated with these investments, as well as greater access to public facilities, goods, and services. In addition, as the communities develop, they become even more attractive to investors, spurring further investments and revitalization.
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2016 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS AMENDMENT (the “Amendment”) is made as of January 5, 2016, by and between Spark Therapeutics, Inc., a Delaware corporation with its principal place of business at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (the “Company”), and Jeffrey D. Marrazzo (the “Executive”).
LICENSE AGREEMENT - AMENDMENT THREELicense Agreement • March 14th, 2016 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
This third Amendment (hereinafter “Amendment Three”) serves as a modification to the License Agreement, having an effective date of October 14, 2013, and having a first amendment with an effective date of December 27, 2013, and a second amendment with an effective date of March 23, 2015, made by and between the University of Iowa Research Foundation, an Iowa Corporation having its principal office at 6 Gilmore Hall, 112 North Capitol Street, Iowa City, Iowa 52242 (hereinafter “UIRF”), and Spark Therapeutics, Inc. (formerly known as AAVenue Therapeutics, LLC) a Delaware Corporation having a principal place of business at 3737 Market Street, Suite 1300 Philadelphia, Pennsylvania, 19104 (hereinafter "Licensee") (the License Agreement together with the first and second amendments hereinafter the “Agreement”).
LICENSE AGREEMENT AMENDMENTLicense Agreement • March 14th, 2016 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment (the "Amendment"), with an effective date of November 23, 2015 (the "Effective Date") serves as a modification to the November 23, 2015 License Agreement made by and between Spark Therapeutics, Inc., a Delaware corporation having a principle place of business at 3737 Market Street, Suite 1300 Philadelphia, Pennsylvania, 19104 ("SPARK" and The Children's Hospital of Philadelphia®, a non-profit entity organized and existing under the laws of Pennsylvania and having a principal place of business at 34th and Civic Center Boulevard, Philadelphia, PA 19104 ("CHOP") (the "0775 Agreement"). Each of SPARK and CHOP may be referred to herein individually as a "Party" and together as the "Parties".
University of Pennsylvania Amended and Restated Patent License AgreementPatent License Agreement • March 14th, 2016 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amended and Restated Patent License Agreement (this “Agreement”) amends and restates that certain Patent License Agreement (the “Original Agreement”) executed and effective as of October 14, 2013 (the “Original Agreement Effective Date”), between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Spark Therapeutics, Inc., a Delaware corporation (“Company”) as successor to AAVenue Therapeutics, LLC, a Delaware limited liability company. This Agreement is being signed on December 31, 2015 (the “Execution Date”). This Agreement will become effective on December 31, 2015 (the “Effective Date”).
Amendment No.1 to Master Research Services Agreement By and Between The Children’s Hospital of Philadelphia and Spark Therapeutics, Inc.Spark Therapeutics, Inc. • March 14th, 2016 • Biological products, (no disgnostic substances)
This amendment is made and entered into March 10, 2016 (the “Effective Date”) by and between The Children’s Hospital of Philadelphia, a Pennsylvania nonprofit corporation with its principal place of business at 34th Street and Civic Center Boulevard, Philadelphia, PA 19104 (“CHOP”) and Spark Therapeutics, Inc., (formerly known as AAVenue Therapeutics, LLC) a Delaware corporation with its principal place of business at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark Therapeutics”) (the “Amendment”).
